Optimized CART Cell Therapy for Metastatic Aggressive Thyroid Cancer

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Thyroid cancer mortality is linked to aggressive, metastatic tumors.
• Chimeric antigen receptor T (CART) cell therapy shows promise but faces challenges like target downregulation.
• Thyroid-stimulating hormone receptor (TSHR) is a target for differentiated thyroid cancers.

Purpose of the Study:

• To develop and evaluate a novel TSHR-targeted CART cell therapy for aggressive thyroid cancers.
• To investigate combination strategies to overcome TSHR downregulation in dedifferentiated thyroid cancers.
• To assess the efficacy of combining TSHR-CART cells with mitogen-activated protein kinase (MAPK) inhibitors.

Main Methods:

• Development of TSHR-targeted CART cells.
• In vitro and in vivo testing against TSHR+ cell lines and patient-derived xenografts.
• Combination therapy using TSHR-CART cells and MAPK inhibitors.

Main Results:

• TSHR-CART cells demonstrated antigen-specific activation and antitumor effects.
• Dedifferentiated thyroid cancers showed TSHR downregulation.
• Combination therapy significantly increased TSHR expression, enhanced antitumor efficacy, and prolonged survival in xenografts compared to monotherapy.

Conclusions:

• TSHR-CART cell therapy is a potential treatment for differentiated thyroid cancers.
• MAPK inhibitors can restore TSHR expression in dedifferentiated thyroid cancers.
• Combination therapy with TSHR-CART cells and MAPK inhibitors offers a potent strategy against aggressive thyroid cancers.